Stockreport

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting [Yahoo! Finance]

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF Represents first study to report time-averaged Lp(a) results to further evaluate potential clinical benefits Data simultaneously published in the Journal of the Ameri [Read more]